Improvement of Blood Plasmalogens and Clinical Symptoms in Parkinson’s Disease by Oral Administration of Ether Phospholipids: A Preliminary Report

Abstract EN

Introduction.

Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease (AD).

With the ageing of population, the frequency of PD is expected to increase dramatically in the coming decades.

L-DOPA (1,3,4-dihydroxyalanine) is the most effective drug in the symptomatic treatment of PD.

Nonmotor symptoms in PD include sleep problems, depression, and dementia, which are not adequately controlled with dopaminergic therapy.

Here, we report the efficacy of oral administration of scallop-derived ether phospholipids to some nonmotor symptoms of PD.

Methods.

Ten (10) patients received oral administration of 1 mg/day of purified ether phospholipids derived from scallop for 24 weeks.

Clinical symptoms and blood tests were checked at 0, 4, 12, 24, and 28 weeks.

The blood levels of plasmalogens in patients with PD were compared with those of 39 age-matched normal controls.

Results.

Initial levels of plasma ethanolamine ether phospholipids in PD and ethanolamine plasmalogen of erythrocyte from PD were lower than those of age-matched normal controls.

Oral administration of 1 mg/day of the purified ether phospholipids increased plasma ether phospholipids in PD and increased the relative composition of ether phospholipids of erythrocyte membrane in PD.

The levels of ether phospholipids in peripheral blood reached to almost normal levels after 24 weeks.

Furthermore, some clinical symptoms of PD improved concomitantly.

Conclusion.

1 mg/day of oral administration of purified ether phospholipids derived from scallop can increase ether phospholipids in peripheral blood and concomitantly improve some clinical symptoms of PD.